GU CANCERS SYMPOSIUM 2024 ROUNDTABLE DISCUSSION: CheckMate914 & Keynote 564
OR
Chair
Dr. Nazanin Fallah-Rad
Panelists
Dr. Sebastien Hotte
Dr. Maria Jiang
This program has been made possible through unrestricted support from EMD Serono & Ipsen
Studies/trials discussed:
- CheckMate914 Study
- Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial
- Keynote 564 Study
- Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma
- Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma
